In Vitro Study of Sequential Fluconazole and Caspofungin Treatment against Candida albicans Biofilms

ABSTRACT Candida albicans biofilms are generally considered to be resistant to azole antifungal agents but susceptible to echinocandins. We demonstrate that in a sequential therapy regimen, treatment with fluconazole first followed by caspofungin leads to a significant decrease of the efficacy of this echinocandin. Cellular stress responses induced by high fluconazole concentrations and mediated by Hsp90 and calcineurin play an important role in this phenomenon.

[1]  P. van Dijck,et al.  Activities of Systemically Administered Echinocandins against In Vivo Mature Candida albicans Biofilms Developed in a Rat Subcutaneous Model , 2013, Antimicrobial Agents and Chemotherapy.

[2]  L. Cowen,et al.  Hsp90 Governs Dispersion and Drug Resistance of Fungal Biofilms , 2011, PLoS pathogens.

[3]  L. Cowen,et al.  Regulatory Circuitry Governing Fungal Development, Drug Resistance, and Disease , 2011, Microbiology and Molecular Reviews.

[4]  J. Lopez-Ribot,et al.  An easy and economical in vitro method for the formation of Candida albicans biofilms under continuous conditions of flow. , 2010, Virulence.

[5]  Arturo Casadevall,et al.  An insight into the antifungal pipeline: selected new molecules and beyond , 2010, Nature Reviews Drug Discovery.

[6]  A. Zaas,et al.  PKC Signaling Regulates Drug Resistance of the Fungal Pathogen Candida albicans via Circuitry Comprised of Mkc1, Calcineurin, and Hsp90 , 2010, PLoS pathogens.

[7]  J. Köhler,et al.  Dispersion as an Important Step in the Candida albicans Biofilm Developmental Cycle , 2010, PLoS pathogens.

[8]  Aimee K. Zaas,et al.  Hsp90 Governs Echinocandin Resistance in the Pathogenic Yeast Candida albicans via Calcineurin , 2009, PLoS pathogens.

[9]  A. Zaas,et al.  Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease , 2009, Proceedings of the National Academy of Sciences.

[10]  L. Cowen,et al.  Stress, Drugs, and Evolution: the Role of Cellular Signaling in Fungal Drug Resistance � , 2022 .

[11]  J. Heitman,et al.  Synergistic Effect of Calcineurin Inhibitors and Fluconazole against Candida albicans Biofilms , 2008, Antimicrobial Agents and Chemotherapy.

[12]  J. Lopez-Ribot,et al.  A simple and reproducible 96-well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing , 2008, Nature Protocols.

[13]  Gordon Ramage,et al.  Candida biofilms on implanted biomaterials: a clinically significant problem. , 2006, FEMS yeast research.

[14]  S. Lindquist,et al.  Hsp90 Potentiates the Rapid Evolution of New Traits: Drug Resistance in Diverse Fungi , 2005, Science.

[15]  C. Kumamoto.  A contact-activated kinase signals Candida albicans invasive growth and biofilm development. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[16]  R. Darouiche,et al.  Candida Infections of Medical Devices , 2004, Clinical Microbiology Reviews.

[17]  Gordon Ramage,et al.  Antifungal Combinations against Candida albicans Biofilms In Vitro , 2003, Antimicrobial Agents and Chemotherapy.

[18]  J. Graybill,et al.  In Vitro Activity of Caspofungin against Candida albicans Biofilms , 2002, Antimicrobial Agents and Chemotherapy.

[19]  B. Wickes,et al.  In Vitro Pharmacodynamic Properties of Three Antifungal Agents against Preformed Candida albicans Biofilms Determined by Time-Kill Studies , 2002, Antimicrobial Agents and Chemotherapy.

[20]  M. Ghannoum,et al.  Antifungal Susceptibility of Candida Biofilms: Unique Efficacy of Amphotericin B Lipid Formulations and Echinocandins , 2002, Antimicrobial Agents and Chemotherapy.

[21]  J. Lopez-Ribot,et al.  Prevalence of Molecular Mechanisms of Resistance to Azole Antifungal Agents in Candida albicans Strains Displaying High-Level Fluconazole Resistance Isolated from Human Immunodeficiency Virus-Infected Patients , 2001, Antimicrobial Agents and Chemotherapy.

[22]  B. Wickes,et al.  Standardized Method for In Vitro Antifungal Susceptibility Testing of Candida albicansBiofilms , 2001, Antimicrobial Agents and Chemotherapy.

[23]  D. McClish,et al.  Nosocomial bloodstream infections in United States hospitals: a three-year analysis. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  C. Beck-Sague,et al.  Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. , 1993, The Journal of infectious diseases.

[25]  W J Martone,et al.  Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. , 1991, The American journal of medicine.